Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Confe...(not welltolerated by many Cystinosis pat...)

Date:6/23/2008

not well tolerated by many Cystinosis patients, who experience severe gastrointestinal distress from the drug. Additionally, the strict, current four times daily dose regimen means that Cystinosis patients must be awakened every night to take the medicine. These side effects and frequent dosing requirements result in non-compliance or skipped doses for many patients. Studies have shown that non-compliance with the current cysteamine bitartrate dose regimen can lead to deteriorating kidney function and other complications.

Based on safety and efficacy studies performed at UCSD, Raptor believes that Cystinosis patients could benefit from a more convenient and superior treatment alternative utilizing DR Cysteamine.

Mr. Daley stated, "We are pleased to have been invited to present at the International Cystinosis Conference. I look forward to sharing results from studies performed at UCSD with a delayed-release form of cysteamine bitartrate which suggest that DR Cysteamine has the potential to become a safer and more effective treatment option for Cystinosis patients and could resolve current non-compliance issues prevalent in this patient population. These findings are supported by the Cystinosis Research Foundation's survey results on the challenges patients face in complying with the current drug's frequent dosing requirements, which I also plan to present. Our goal is to improve the quality of life of the Cystinosis patients and their families."

Raptor plans to initiate an expanded study of its final proprietary DR Cysteamine formulation in collaboration with the UCSD clinical researchers in 2009.

About Cystinosis Foundation Ireland and the International Cystinosis Conference

Cystinosis Foundation Ireland was set up in 2003 to support Cystinosis patients and their families. The goal of the Foundation is to raise awareness about Cystinosis and support research through its fundraising efforts. The International Cystinosis Conference
'/>"/>

SOURCE Raptor Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
2. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
3. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
4. Raptor Pharmaceuticals Acquires Orphan Clinical Program
5. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
6. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
8. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
9. GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives
10. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
11. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals